Attached files

file filename
8-K - FORM 8-K - SIRONA DENTAL SYSTEMS, INC.d8k.htm

Exhibit 99.1

LOGO

Sirona Reports Fiscal 2011 Second Quarter Results

 

   

Second quarter revenues were $214.7 million, up 12.9% compared to prior year, and up 14.0% constant currency.

 

   

Second quarter 2011 operating income of $33.5 million plus amortization of $13.5 million totaled $47.0 million, up 2.0% versus prior year.

 

   

Sirona increases FY11 guidance - revenue growth of 13% to 16% constant currency (prev. 9% to 12%) and operating income excluding amortization expense of $214 to $221 million (prev. $208 to $216 million).

Long Island City, New York, May 6, 2011 – Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the quarter ended March 31, 2011.

Second Quarter Fiscal 2011 vs. Second Quarter Fiscal 2010 Financial Results

Revenue was $214.7 million, an increase of $24.6 million or up 12.9% (up 14.0% on a constant currency basis), with growth rates for the Company’s business segments as follows: Imaging Systems increased 21.4% (up 22.2% constant currency); CAD CAM increased 16.1% (up 17.0% constant currency); Treatment Centers increased 3.4% (up 4.8% on a constant currency basis); and Instruments declined 1.3% (flat constant currency). Revenue in the United States increased 2.9%, while revenues outside the United States increased 17.5% (up 19.0% constant currency), with strong growth in Germany, other European markets and solid performance in Asia Pacific.

Gross profit was $115.7 million, up $16.4 million. Gross profit margin was 53.9% in the second quarter of Fiscal 2011, compared to 52.2% in the prior year. The gross profit margin expansion was mainly driven by lower levels of amortization expense.

Second quarter 2011 operating income excluding amortization expense was $47.0 million (operating income of $33.5 million plus amortization expense of $13.5 million), compared to $46.1 million (operating income of $30.6 million plus amortization expense of $15.5 million) in the second quarter of 2010.

Net income for the second quarter of 2011 was $29.3 million, or $0.51 per diluted share, versus $17.5 million, or $0.31 per diluted share in the prior year period. Non-GAAP earnings per diluted share for the second quarter of 2011 was $0.58 compared to $0.64 in the second quarter of 2010.

At March 31, 2011, the Company had cash and cash equivalents of $300.1 million and total debt of $382.2 million, resulting in net debt of $82.1 million. This compares to net debt of $119.0 million at September 30, 2010.

 

Page 1


Jost Fischer, Chairman and CEO of Sirona commented: “I am pleased to report another quarter of solid execution and strong revenue growth for Sirona. Our performance was particularly encouraging given the timing of the International Dental Show (“IDS”) in March, as dentists have usually postponed purchases in anticipation of the show. The quarter saw continued robust sales in international markets, with strong growth in Germany, other European markets and Asia Pacific. Our solid financial performance is the direct result of our strategy to make significant investments in both research and development and in expanding our global footprint.”

Mr. Fischer continued: “The highlight of the quarter was our strong showing at the IDS which once again confirmed Sirona’s leadership position as the premier provider of innovative high-tech dental products. At the show, the Company introduced a wide range of new products, ensuring that Sirona will continue to lead the dental industry’s conversion to digital dentistry. As a result of our encouraging business trends, and the ongoing momentum in international markets, we are increasing our guidance.”

Fiscal 2011 Guidance

Management now anticipates constant currency revenue growth in the range of 13% to 16% (previously 9% to 12%), and operating income, excluding amortization estimated at $54 million for fiscal 2011, to be in the range of $214 to $221 million (compared to previous guidance of $208 to $216 million).

First Six Months Fiscal 2011 vs. First Six Months Fiscal 2010 Financial Results

Revenue was $450.4 million, an increase of $45.4 million or up 11.2% (up 14.9% constant currency) with growth rates for the Company’s business segments as follows: CAD CAM Systems increased 14.5% (up 17.6% constant currency); Imaging Systems increased 13.8% (up 16.3% constant currency); Treatment Centers increased 8.6% (up 14.0% constant currency); and Instruments declined 0.5% (up 4.3% constant currency). Revenue in the United States increased 1.8%. Outside the United States, revenue increased 15.5% (up 21.2% constant currency) driven by solid performance in Europe, led by Germany, as well in the Asia Pacific and Middle East markets.

Gross profit increased by $34.4 million to $246.1 million, up 16.2%. Gross profit margins expanded 240 basis points to 54.6 percent, driven by strong revenue growth, favorable product mix and lower levels of amortization expense.

First six months 2011 operating income excluding amortization expense was $116.5 million (operating income of $89.5 million plus amortization expense of $27.0 million), up 10.2% compared to $105.8 million (operating income of $74.1 million plus amortization expense of $31.7 million) in the prior year.

Conference Call/Webcast Information

Sirona will hold a conference call to discuss its financial results at 8:30 AM Eastern Time on May 6, 2011. The teleconference can be accessed by calling +1 866 730 5762 (domestic) or +1 857 350 1586 (international) using passcode # 18531976. The webcast will be available via the Internet at http://ir.sirona.com and a presentation relating to the call will be available on our website. A replay of the

 

Page 2


conference call will be available through May 13, 2011 by calling +1 888 286 8010 (domestic) or +1 617 801 6888 (international) using passcode # 64084965. A web archive will be available for 30 days at www.sirona.com.

About Sirona Dental Systems, Inc.

Sirona, the dental technology leader, has served dealers and dentists worldwide for more than 130 years. Sirona develops, manufactures, and markets a complete line of dental products, including CAD CAM restoration systems (CEREC), digital intra-oral, panoramic and 3D imaging systems, dental treatment centers and handpieces. Visit http://www.sirona.com for more information about Sirona and its products.

Contact information:

John Sweeney, CFA

Vice President, Investor Relations

Sirona Dental Systems, Inc.

+1 718 482 2184

john.sweeney@sirona.com

This press release contains forward-looking information about Sirona Dental Systems, Inc.’s financial results, guidance and estimates, business prospects, and products and services that involve substantial risks and uncertainties or other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You can identify these statements by the use of words such as “may,” “could,” “estimate,” “will,” “believe,” “anticipate,” “think,” “intend,” “expect,” “project,” “plan,” “target,” “forecast”, and similar words and expressions which identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and involve known and unknown risks and uncertainties, and other factors. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. For a discussion of such risks, uncertainties and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental product and services, pricing, future sales volume of the Company’s products, the possibility of changing economic, market and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, acquisitions and affiliations and currency exchange rate fluctuations, readers are urged to carefully review and consider various disclosures made by the Company in its Annual Report on Form 10-K and in its reports on Forms 10-Q and 8-K filed with the U.S. Securities and Exchange Commission, which can be accessed through the SEC’s website, www.sec.gov. This presentation contains non GAAP financial measures, which should not be viewed in isolation and do not purport to be an alternative to net income (loss) as an indicator of operating performance or an alternative to cash flows from operating activities as a measure of liquidity. The Company assumes no obligation to and expressly disclaims any obligation to update or revise any forward-looking statements contained in this document to reflect new information or future events or developments after the date any such statement is made.

 

Page 3


SIRONA DENTAL SYSTEMS, INC.

AND SUBSIDIARIES

CONDENSED CONSOLIDATED INCOME STATEMENT

(UNAUDITED)

 

     Three months ended
March 31,
    Six months ended
March 31,
 
     2011     2010     2011     2010  
     $’000s (except per share amounts)     $’000s (except per share amounts)  

Revenue

   $ 214,737      $ 190,136      $ 450,383      $ 404,959   

Cost of sales

     99,048        90,803        204,280        193,256   
                                

Gross profit

     115,689        99,333        246,103        211,703   

Selling, general and administrative expense

     70,581        60,354        133,904        120,206   

Research and development

     14,145        11,690        27,655        23,155   

Provision for doubtful accounts and notes receivable

     (47     72        21        136   

Net other operating income

     (2,500     (3,408     (5,000     (5,908
                                

Operating income

     33,510        30,625        89,523        74,114   

(Gain)/Loss on foreign currency transactions, net

     (4,336     5,049        (5,097     4,416   

(Gain)/Loss on derivative instruments

     (1,554     (1,712     81        (2,735

Interest expense, net

     929        4,141        1,879        9,343   

Other expense/(income)

     343        404        (523     784   
                                

Income before taxes

     38,128        22,743        93,183        62,306   

Income tax provision

     8,388        4,548        20,500        12,461   
                                

Net income

     29,740        18,195        72,683        49,845   

Less: Net income attributable to noncontrolling interests

     428        656        979        1,131   
                                

Net income attributable to Sirona Dental Systems, Inc.

   $ 29,312      $ 17,539      $ 71,704      $ 48,714   
                                

Income per share (attributable to Sirona Dental Systems, Inc. common shareholders):

        

- Basic

   $ 0.53      $ 0.32      $ 1.29      $ 0.88   

- Diluted

   $ 0.51      $ 0.31      $ 1.26      $ 0.86   

Weighted average shares-basic

     55,529,619        55,122,944        55,432,272        55,044,832   

Weighted average shares-diluted

     57,221,163        56,610,111        57,056,605        56,490,563   

 

Page 4


SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

     March 31,
2011
    September 30,
2010
 
     (unaudited)        
     $’000s (except per share amounts)  

ASSETS

    

Current assets

    

Cash and cash equivalents

   $ 300,136      $ 251,767   

Restricted cash

     710        703   

Accounts receivable, net of allowance for doubtful accounts of $1,639 and $1,681, respectively

     113,245        82,952   

Inventories, net

     90,489        74,027   

Deferred tax assets

     24,005        20,570   

Prepaid expenses and other current assets

     15,097        24,139   

Income tax receivable

     4,948        3,533   
                

Total current assets

     548,630        457,691   

Property, plant and equipment, net of accumulated depreciation and amortization of $105,443 and $90,713, respectively

     118,225        102,686   

Goodwill

     677,610        656,465   

Investments

     2,364        2,317   

Intangible assets, net of accumulated amortization of $401,167 and $371,303, respectively

     346,495        362,722   

Other non-current assets

     2,773        2,229   

Deferred tax assets

     4,077        8,827   
                

Total assets

   $ 1,700,174      $ 1,592,937   
                

LIABILITIES AND SHAREHOLDERS’ EQUITY

    

Current liabilities

    

Trade accounts payable

   $ 48,167      $ 42,737   

Short-term debt and current portion of long-term debt

     382,223        2,935   

Income taxes payable

     7,955        7,748   

Deferred tax liabilities

     1,211        1,456   

Accrued liabilities and deferred income

     89,201        105,209   
                

Total current liabilities

     528,757        160,085   

Long-term debt

     —          367,801   

Deferred tax liabilities

     134,014        138,190   

Other non-current liabilities

     6,453        6,556   

Pension related provisions

     55,418        52,672   

Deferred income

     55,000        60,000   
                

Total liabilities

     779,642        785,304   
                

Shareholders’ equity

    

Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued and outstanding)

     0        0   

Common stock ($0.01 par value; 95,000,000 shares authorized; 55,768,804 shares issued and 55,741,081 shares outstanding at Mar. 31, 2011, and 55,333,304 shares issued and 55,305,581 shares outstanding at Sept. 30, 2010)

     558        553   

Additional paid-in capital

     665,305        652,698   

Treasury stock (27,723 shares at cost)

     (284     (284

Excess of purchase price over predecessor basis

     (49,103     (49,103

Retained earnings

     253,550        181,846   

Accumulated other comprehensive income

     47,650        19,701   
                

Total Sirona Dental Systems, Inc. shareholders’ equity

     917,676        805,411   
                

Noncontrolling interests

     2,856        2,222   
                

Total shareholders’ equity

     920,532        807,633   
                

Total liabilities and shareholders’ equity

   $ 1,700,174      $ 1,592,937   
                

 

Page 5


SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

     Six months ended March 31,  
     2011     2010  
     $’000s  

Cash flows from operating activities

    

Net income

   $ 72,683      $ 49,845   

Adjustments to reconcile net income to net cash provided by operating activities

  

Depreciation and amortization

     38,957        42,589   

Loss on disposal of property, plant and equipment

     —          15   

Loss/(gain) on derivative instruments

     81        (2,735

(Gain)/loss on foreign currency transactions

     (5,097     4,416   

Deferred income taxes

     (7,250     (9,491

Amortization of debt issuance cost

     597        586   

Share-based compensation expense

     4,479        8,048   

Changes in assets and liabilities

    

Accounts receivable

     (27,467     (7,288

Inventories

     (13,280     (3,601

Prepaid expenses and other current assets

     9,803        6,701   

Restricted cash

     20        109   

Other non-current assets

     (735     26   

Trade accounts payable

     3,957        3,353   

Accrued interest on long-term debt

     —          (1,412

Accrued liabilities and deferred income

     (20,663     (25,309

Other non-current liabilities

     234        4,037   

Income taxes receivable

     (1,410     1,506   

Income taxes payable

     (292     3,415   
                

Net cash provided by operating activities

     54,617        74,810   

Cash flows from investing activities

    

Investment in property, plant and equipment

     (23,618     (9,566

Proceeds from sale of property, plant and equipment

     1        150   

Purchase of intangible assets

     (163     —     

Purchase of long-term investments

     (44     (230

Sale of businesses, net of cash sold

     —          1,928   
                

Net cash used in investing activities

     (23,824     (7,718

Cash flows from financing activities

    

Repayments of short-term and long-term debt

     —          (78,072

Dividend distributions to noncontrolling interest

     (487     —     

Common shares issued under share based compensation plans

     4,709        2,973   

Tax effect of common shares exercised under share based compensation plans

     4,135        1,181   
                

Net cash provided by/(used in) financing activities

     8,357        (73,918

Change in cash and cash equivalents

     39,150        (6,826

Effect of exchange rate change on cash and cash equivalents

     9,219        (11,833

Cash and cash equivalents at beginning of period

     251,767        181,098   
                

Cash and cash equivalents at end of period

   $ 300,136      $ 162,439   
                

Supplemental information

    

Interest paid

   $ 2,050      $ 10,381   

Interest capitalized

     277        242   

Income taxes paid

     24,798        18,478   

 

Page 6


Non-GAAP Financial Measures (unaudited)

 

     Three months ended March 31, 2011  
     Pre Tax     Tax Impact*     After Tax     Per Diluted
Share
 
     $’000s        

GAAP net income attributable to Sirona Dental Systems, Inc. shareholders

       $ 29,312      $ 0.51   

Adjustments

        

Amortization and depreciation expense resulting from the step-up to fair values of intangible assets related to past business combinations

   $ 13,192      $ 2,902      $ 10,290     

Unrealized, non-cash (gain) on revaluation of the carrying value of the $-denominated exclusivity fee

     (3,878     (853     (3,025  

Unrealized, non-cash (gain) on revaluation of the carrying value of short-term intra-group loans

     (4,347     (956     (3,391  
                    

Non-GAAP adjusted net income

       $ 33,186      $ 0.58   
                    
     Three months ended March 31, 2010  
     Pre Tax     Tax Impact*     After Tax     Per Diluted
Share
 
     $’000s        

GAAP net income attributable to Sirona Dental Systems, Inc. shareholders

       $ 17,539      $ 0.31   

Adjustments

        

Amortization and depreciation expense resulting from the step-up to fair values of intangible assets related to past business combinations

   $ 15,088      $ 3,018      $ 12,070     

Unrealized, non-cash loss on revaluation of the carrying value of the $-denominated exclusivity fee

     5,099        1,020        4,079     

Unrealized, non-cash loss on revaluation of the carrying value of short-term intra-group loans

     4,404        881        3,523     

Gain on sale of Subsidiary

     (908     (182     (726  
                    

Non-GAAP adjusted net income

       $ 36,485      $ 0.64   
                    
     Six months ended March 31, 2011  
     Pre Tax     Tax Impact*     After Tax     Per Diluted
Share
 
     $’000s        

GAAP net income attributable to Sirona Dental Systems, Inc. shareholders

       $ 71,704      $ 1.26   

Adjustments

        

Amortization and depreciation expense resulting from the step-up to fair values of intangible assets related to past business combinations

   $ 26,338      $ 5,794      $ 20,544     

Unrealized, non-cash (gain) on revaluation of the carrying value of the $-denominated exclusivity fee

     (2,470     (543     (1,927  

Unrealized, non-cash (gain) on revaluation of the carrying value of short-term intra-group loans

     (3,001     (660     (2,341  
                    

Non-GAAP adjusted net income

       $ 87,980      $ 1.54   
                    
     Six months ended March 31, 2010  
     Pre Tax     Tax Impact*     After Tax     Per Diluted
Share
 

GAAP net income attributable to Sirona Dental Systems, Inc. shareholders

       $ 48,714      $ 0.86   

Adjustments

        

Amortization and depreciation expense resulting from the step-up to fair values of intangible assets related to past business combinations

   $ 30,898      $ 6,180      $ 24,718     

Unrealized, non-cash loss on revaluation of the carrying value of the $-denominated exclusivity fee

     6,451        1,290        5,161     

Unrealized, non-cash loss on revaluation of the carrying value of short-term intra-group loans

     5,671        1,134        4,537     

Gain on sale of Subsidiary

     (908     (182     (726  
                    

Non-GAAP adjusted net income

       $ 82,404      $ 1.46   
                    

 

* tax impact calculated using estimated effective tax rate of 22% for second quarter and first half of FY11 and 20% for second quarter and first half of FY10

 

Page 7


To supplement our consolidated financial statements and our business outlook, we use the following non-GAAP financial measures: non-GAAP adjusted net income, and non-GAAP adjusted earnings per diluted share, which exclude, as applicable, amortization and depreciation expense resulting from the step-up to fair values of intangible and tangible assets related to past business combinations, unrealized, non-cash loss/(gain) on revaluation of the carrying value of the $-denominated exclusivity fee, unrealized, non-cash loss/(gain) on revaluation of the carrying value of short-term intra-group loans and any related tax effects.

Management recognizes that the use of these non-GAAP measures has limitations, including the fact that they might not be comparable with similar non-GAAP measures used by other companies and that management must exercise judgment in determining which types of charges and other items should be excluded from its non-GAAP financial measures. Management currently compensates for these limitations by providing full disclosure of each non-GAAP financial measure and a reconciliation to the most directly comparable GAAP measure. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We use these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our “core operating performance”. Management believes that “core operating performance” represents Sirona’s operating performance in the ordinary, ongoing and customary course of its operations. Accordingly, management excludes from “core operating performance” the impact of acquisition-related intangible depreciation and amortization in order to compare our underlying financial performance to prior periods, certain non-cash charges related to currency revaluation that do not reflect our period-to-period operating performance, and to the extent relevant in a particular period, any other cash or non-cash items that management does not view as indicative of its on-going operating performance. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal evaluation of period-to-period comparisons. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making and (2) they are provided to and used by our institutional investors and the analyst community to facilitate comparisons with prior and subsequent reporting periods.

Constant Currency: We have included certain revenue information in this press release on a constant currency basis. This information is a non-GAAP financial measure. We supplementally present revenue on a constant currency basis because we believe it facilitates a comparison of our operating results from period to period without regard to changes resulting solely from fluctuations in currency rates. Sirona calculates constant currency revenue growth by comparing current period revenues to prior period revenues with both periods converted at the U.S. Dollar/Euro average foreign exchange rate for each month of the current period.

The average exchange rate for the six months ended March 31, 2011, was $1.36368 and varied from $1.40040 to $1.32171. For the three and six months ended March 31, 2010, an average quarterly exchange rate converting Euro denominated revenues into U.S. Dollars of $1.38559 and $1.43182, respectively, was applied.

 

Page 8